Professor, Internal Medicine and Oncology, Mayo Medical School
Oncology
Dr. Frank A. Sinicrope, MD
|
|
Give Review
Frank Sinicrope is an expert in the field of Oncology. He studied medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine Frank A. Sinicrope is a published doctor. He has 101 publications published. The most current publication "bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome." He accepts Medicare.
Publications
- Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon Cancer patients: NCCTG N0147 (Alliance).
- Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangioCarcinoma cells.
- An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
- Association between molecular subtypes of coloRectal cancer and patient survival.
- Molecular markers identify subtypes of stage III colon Cancer associated with patient outcomes.
- Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer.
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance).
- Association Study of the let-7 miRNA-Complementary Site Variant in the 3' Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial).
- Aspirin and coloRectal cancer: back to the future.
- Aflibercept and its role in the treatment of coloRectal cancer--letter.
- p62/Sequestosome-1 Up-regulation Promotes ABT-263-induced Caspase-8 Aggregation/Activation on the Autophagosome.
- HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenoCarcinoma.
- Mutation-specific antibody detects mutant BRAF(V600E) protein expression in human colon Carcinomas.
- Body mass index at diagnosis and survival among colon Cancer patients enrolled in clinical trials of adjuvant chemotherapy.
- Serrated Colon Polyps as Precursors to ColoRectal Cancer.
- Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon Carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy.
- Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon Carcinomas.
- Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenoCarcinomas.
- Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant ...
- A population-based study of prevalence and adherence trends in average risk coloRectal cancer screening, 1997-2008.
- Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenoCarcinoma.
- Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy inDuction and downregulation of p62/sequestosome 1.
- The role of autophagy in Cancer: therapeutic implications.
- The future role of the gastroenterologist in Digestive oncology: an international perspective.
- DNA mismatch repair status and colon Cancer recurrence and survival in clinical trials of 5-Fluorouracil-based adjuvant therapy.
- Evaluation of Difluoromethylornithine for the Chemoprevention of Barrett's Esophagus and Mucosal Dysplasia.
- Obesity and breast Cancer prognosis: weight of the evidence.
- The prognostic value of clinical and pathologic factors in esophageal adenoCarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.
- Targeted therapeutic agents for coloRectal cancer.
- Obesity is an independent prognostic variable in colon Cancer survivors.
- A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangioCarcinoma cells.
- Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic Cancer cells.
- Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human coloRectal cancer cells.
- Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon Carcinoma.
- Clinical implications of microsatellite instability in sporadic colon Cancers.
- BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic Cancer cells.
- Induction of Noxa sensitizes human coloRectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
- Prognostic impact of bim, puma, and noxa expression in human colon Carcinomas.
- Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon Cancers.
- BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic Cancer cells.
- A moveable feast.
- Alterations in cell proliferation and apoptosis in colon Cancers with microsatellite instability.
- Sporadic coloRectal cancer: an infectious disease?
- Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon Cancers.
- Prognostic impact of microsatellite instability and DNA ploidy in human colon Carcinoma patients.
- Advances in chemotherapy for coloRectal cancer.
- Targeting cyclooxygenase-2 for prevention and therapy of coloRectal cancer.
- Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci.
- Thymidylate synthase expression in colon Carcinomas with microsatellite instability.
- PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic Cancer cells.
- Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon Cancer cells overexpressing Bcl-2.
- N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon Cancer.
- Insights into familial colon Cancer: the plot thickens.
- ColoRectal cancer prevention: is an ounce of prevention worth a pound of cure?
- Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis inDuction by sulindac sulfide in human colon carcinoma cells.
- Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the Small molecule Bcl-2 inhibitor, HA 14-1, in human c...
- Treating polyps in Ulcerative colitis: adenoma-like lesions and dysplasia-associated mass lesions.
- HER-2 receptor expression, localization, and activation in coloRectal cancer cell lines and human tumors.
- Role of cyclooxygenase-2 in coloRectal cancer.
- Low overexpression of HER-2/neu in advanced coloRectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
- Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon Cancer cells.
- Radiation Enteritis.
- Cyclooxygenase-2 expression in human breast Cancers and adjacent ductal carcinoma in situ.
- Post-study aspirin intake and factors motivating participation in a coloRectal cancer chemoprevention trial.
- A dose-finding study of aspirin for chemoprevention utilizing Rectal mucosal prostaglandin E(2) levels as a biomarker.
- InDuction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon c...
- Chemoprevention of coloRectal cancer.
- Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human coloRectal carcinoma.
- Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon Cancer.
- Autophagy modulation for Cancer therapy.
- Serrated polyps of the colon.
- Prognostic and predictive impact of DNA mismatch repair in the management of coloRectal cancer.
- Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon Cancer patients.
- DNA mismatch repair and adjuvant chemotherapy in sporadic colon Cancer.
- Prognostic effect of activated EGFR expression in human colon Carcinomas: comparison with EGFR status.
- Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus Cancer.
- Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon Cancer cells.
- Is ursodeoxycholic acid effective for the prevention of coloRectal adenoma recurrence?
- Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci.
- Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver cAnalicular membrane vesicles.
- Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
- Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosi...
- Role of adjuvant therapy in surgically resected coloRectal carcinoma.
- bcl-2 and p53 oncoprotein expression during coloRectal tumorigenesis.
- Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon Carcinoma to local invasion, DNA ploidy, and disease relapse.
- Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis.
- Interobserver variability in endoscopic ultrasonography: a prospective evaluation.
- Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic coloRectal neoplasms but not hereditary nonpolyposis coloRectal cancers.
- Prognostic value of bcl-2 oncoprotein expression in stage II colon Carcinoma.
- Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon Carcinoma.
- Increased apoptosis accompanies neoplastic development in the human colorectum.
- bcl-2 and p53 expression in resectable pancreatic adenoCarcinomas: association with clinical outcome.
- Loci for efficient detection of microsatellite instability in hereditary non-polyposis coloRectal cancer.
- Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis coloRectal cancers relative to sporadic cancers.
- Apoptotic and mitotic indices predict survival rates in lymph node-negative colon Carcinomas.
- Prognostic factors in resectable pancreatic Cancer: p53 and bcl-2.
- Increased cyclooxygenase-2 expression in human pancreatic Carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
- ColoRectal cancer prevention and treatment.
- Aberrant methylation of the Cyclooxygenase 2 CpG island in coloRectal tumors.
- VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Schools
University Of ChicagoThe Pritzker School Of Medicine
Michael Reese Hospital and Med Center
MD Anderson Cancer Center University Texas
University Chicago Hospital
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
University of Chicago -
University of Chicago Pritzker School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1144200353 | |
| NPPES Provider LastName | SINICROPE | |
| NPPES Provider FirstName | FRANK | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 27.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1144200353 |
| Last Name Of The Provider | SINICROPE |
| First Name Of The Provider | FRANK |
| View All |
Similar Doctors
|
|
Dr. Harry H. Yoon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles L. Loprinzi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Nayantara Coelho-Prabhu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Liu Yang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Hobday, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert C. Miller, MD |
|
|
Dr. Andres J. Acosta Cardenas, MD |
|
|
Dr. Axel F. Grothey, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andreas S. Beutler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason S. Puckett, MD
This Doctor is OpenDoctor Recommended.
|